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L E T T E R T O TH E E D I T O R
Myocardial fibrosis and arrhythmogenesis in elite athletes
To the Editor,
Cuspidi et al present an excellent meta-analysis of nine studies
involving 403 elite athletes and 297 controls investigating volumetric
and strain analysis of left atrial (LA) phasic function.1 Salient conclu-
sions of their analysis include that the LA volume is higher and LA res-
ervoir and contractile functions are impaired in elite athletes during
active training when compared to the controls. The authors also con-
clude that the LA remodeling and contractile dysfunction may provide
a substrate for the development of atrial and ventricular tachyarrhyth-
mias. We wish to highlight a few additional points.
In addition to the LA remodeling that contributes to arrhythmogenesis,
there is substantial evidence that endurance athletes are prone to develop
myocardial fibrosis (patchy, interstitial, or dense scar) which can also trig-
ger arrhythmias.2,3 The myocardial fibrosis can be focal or diffuse and can
develop in the right or left ventricle, septum, papillary muscles, or bundle
branches.2 Cardiac magnetic resonance imaging using late gadolinium
enhancement has detected myocardial fibrosis in endurance athletes.4 In
addition, these findings have been supported by murine models and small
post-mortem studies on human subjects.2 Cardiac fibroblasts are normal
cell types occurring in healthy hearts and are responsible for extracellular
matrix homeostasis, but upon exposure to injury, mechanical stress, or
inflammation, these cells may transform into myofibroblasts and induce
cardiac fibrosis.3 Sequelae of this pathologic remodelingmay includemyo-
cardial stiffness (increasing ventricular end-diastolic pressures), chamber
dilation, hypertrophy, and ultimately heart failure.2,3
The cardiovascular benefits of exercise are well accepted but the
tipping point where the physiologic remodeling becomes pathologic is
yet somewhat unclear. The authors are to be commended for adding
to our fund of knowledge for this burgeoning field. Characterization
of at-risk elite athletes is important because of the risk of arrhythmias
and consequently, sudden cardiac death as these may be preventable.
A risk prediction model should be established incorporating LA volu-
metric and strain data from the present study, myocardial fibrosis
from the imaging studies, and other established criteria. Future studies
should also aim to provide a risk prediction clinical tool to decrease
the arrhythmia related morbidity and mortality in elite athletes.
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